PMID- 34224438 OWN - NLM STAT- MEDLINE DCOM- 20220316 LR - 20231108 IS - 1533-4058 (Electronic) IS - 1541-2016 (Print) IS - 1533-4058 (Linking) VI - 30 IP - 1 DP - 2022 Jan 1 TI - Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study. PG - 27-35 LID - 10.1097/PAI.0000000000000949 [doi] AB - We performed a pilot study in anticipation of using long-aged precut formalin-fixed paraffin-embedded tissue sections stored in real-world conditions for translational biomarker studies of topoisomerase 2A (TOP2A), Ki67, and human epidermal growth factor receptor 2 (HER2) in endometrial cancer. Formalin-fixed paraffin-embedded tissue blocks or unstained slides or both from GOG-0177 were collected centrally (1999-2000) and stored at room temperature. During 2004 to 2011 specimens were stored at 4 degrees C. Matched pairs of stored slides and freshly cut slides from stored blocks were analyzed for TOP2A (KiS1), Ki67 (MIB1), and HER2 (HercepTest) proteins. To assess DNA stability (HER2 PathVision), fluorescence in situ hybridization (FISH) was repeated on stored slides from 21 cases previously shown to be HER2 amplified. Immunohistochemistry (IHC) staining intensity and extent, mean FISH copies/cell, and copy number ratios were compared using the kappa statistic for concordance or signed rank test for differences in old cut versus new cut slides. IHC results reflected some protein degradation in stored slides. The proportion of cells with TOP2A staining was lower on average by 12% in older sections (P=0.03). The proportion of Ki67-positive cells was lower in stored slides by an average of 10% (P<0.01). Too few cases in the IHC cohort were FISH positive for any conclusions. HER2 amplification by FISH was unaffected by slide storage. We conclude that use of aged stored slides for proliferation markers TOP2A and Ki67 is feasible but may modestly underestimate true values in endometrial cancer. Pilot studies for particular storage conditions/durations/antigens to be used in translational studies are warranted. CI - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. FAU - Grushko, Tatyana A AU - Grushko TA AD - Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, University of Chicago. FAU - Filiaci, Virginia L AU - Filiaci VL AD - NRG Oncology Statistics and Data Management Center, Roswell Park Comprehensive Cancer Center, Buffalo, NY. FAU - Montag, Anthony G AU - Montag AG AD - Department of Pathology, The University of Chicago Medical Center, Chicago, IL. FAU - Apushkin, Marsha AU - Apushkin M AD - Department of Pathology, The University of Chicago Medical Center, Chicago, IL. FAU - Gomez, Maria J AU - Gomez MJ AD - Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, University of Chicago. FAU - Monovich, Laura AU - Monovich L AD - Gynecologic Oncology Group Tissue Bank/NRG Oncology Biospecimen Bank, Biopathology Center, Research Institute at Nationwide Children's Hospital, Columbus, OH. FAU - Ramirez, Nilsa C AU - Ramirez NC AD - Gynecologic Oncology Group Tissue Bank/NRG Oncology Biospecimen Bank, Biopathology Center, Research Institute at Nationwide Children's Hospital, Columbus, OH. FAU - Schwab, Carlton AU - Schwab C AD - Gibbs Cancer Center and Research Institute, Spartanburg, SC. FAU - Kesterson, Joshua P AU - Kesterson JP AD - Division of Gynecologic Oncology, Penn State Hershey Medical Center, Hershey, PA. FAU - Seward, Shelly M AU - Seward SM AD - The Women's Healing Center, a division of HCA, Orlando, FL. FAU - Method, Michael W AU - Method MW AD - Division of Gynecological Oncology, Indiana University Hospital/Melvin and Bren Simon Cancer Center; Indianapolis, IN. FAU - Olopade, Olufunmilayo I AU - Olopade OI AD - Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, University of Chicago. FAU - Fleming, Gini F AU - Fleming GF AD - Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, University of Chicago. FAU - Birrer, Michael J AU - Birrer MJ AD - University of Arkansas for Medical Sciences, Little Rock, AR. LA - eng SI - ClinicalTrials.gov/NCT01164735 GR - U10 CA180868/CA/NCI NIH HHS/United States GR - U24 CA114793/CA/NCI NIH HHS/United States GR - K12 CA139160/CA/NCI NIH HHS/United States GR - UL1 RR024999/RR/NCRR NIH HHS/United States GR - P30 CA014599/CA/NCI NIH HHS/United States GR - U10 CA027469/CA/NCI NIH HHS/United States GR - U10 CA037517/CA/NCI NIH HHS/United States GR - UG1 CA233191/CA/NCI NIH HHS/United States GR - U10 CA180822/CA/NCI NIH HHS/United States PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't PL - United States TA - Appl Immunohistochem Mol Morphol JT - Applied immunohistochemistry & molecular morphology : AIMM JID - 100888796 RN - EC 2.7.10.1 (Receptor, ErbB-2) SB - IM MH - Aged MH - *Breast Neoplasms MH - *Endometrial Neoplasms/diagnosis MH - Female MH - Humans MH - Immunohistochemistry MH - In Situ Hybridization, Fluorescence MH - Pilot Projects MH - Receptor, ErbB-2/metabolism PMC - PMC8664981 MID - NIHMS1703058 COIS- V.L.F.: grants from NIH during the conduct of this study and additional funding from GOG Foundation Inc. outside the submitted work for other gynecologic clinical trials. S.M.S.: speakers Burea for GSK (Zejula), AstraZeneca (Olaparib), and Merk (Keytruda+lenvatanib). T.A.G.: current employee of Abbott. M.W.M.: current employee of Lilly and own Lilly stock. G.F.F.: Ad board for GSK, institutional PI for industry trials of Roche, Syros, GSK, Iovance, Sanofi, Sermonix, Incyte, Compugen, Abbvie, Eisai, Celldex, Astra Zeneca, Corcept, Merck, Plexxicon. The remaining authors declare no conflict of interest. EDAT- 2021/07/06 06:00 MHDA- 2022/03/17 06:00 PMCR- 2023/01/01 CRDT- 2021/07/05 17:13 PHST- 2020/12/17 00:00 [received] PHST- 2021/04/13 00:00 [accepted] PHST- 2021/07/06 06:00 [pubmed] PHST- 2022/03/17 06:00 [medline] PHST- 2021/07/05 17:13 [entrez] PHST- 2023/01/01 00:00 [pmc-release] AID - 00129039-202201000-00005 [pii] AID - 10.1097/PAI.0000000000000949 [doi] PST - ppublish SO - Appl Immunohistochem Mol Morphol. 2022 Jan 1;30(1):27-35. doi: 10.1097/PAI.0000000000000949.